Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Linn

Showing results (131-140 of 467) with videos related to

Pageof 47
Sort By:
FEBS Letters|October 31, 2006
Functional characterization of the promoter for the mouse SPTLC2 gene, which encodes subunit 2 of serine palmitoyltransferaseStephen C Linn, Lindsay M Andras, Hee-Sook Kim, et al.
Breast (Edinburgh, Scotland)|October 3, 2015
St. Gallen endocrine response classes predict recurrence rates over timeR H T Koornstra, K J Beelen, A D Vincent, et al.
JCO Precision Oncology|February 17, 2022
Profound Immunotherapy Response in Mismatch Repair-Deficient Breast CancerMarleen Kok, Hugo M Horlings, Petur Snaebjornsson, et al.
British Journal of Cancer|November 18, 2010
Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signatureM Knauer, F Cardoso, J Wesseling, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Microsimulation Model For The Assessment Of Personalized Cancer Care: The Mapcca Model FrameworkE Van der Meijde, A J van den Eertwegh, R J Fijneman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 10, 2011
Risk of hepatitis B reactivation and the role of novel agents and stem-cell transplantation in multiple myeloma patients with hepatitis B virus (HBV) infectionD H T Mya, S T Han, Y C Linn, et al.
Breast Cancer Research and Treatment|August 19, 2016
Erratum to: The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancerMette S van Ramshorst, Margriet van der Heiden-van der Loo, Gwen M H E Dackus, et al.
Familial Cancer|September 16, 2022
Identifying the BRCA1 c.-107A > T variant in Dutch patients with a tumor BRCA1 promoter hypermethylationVincent M T de Jong, Roelof Pruntel, Tessa G Steenbruggen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 23, 2009
The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatmentJ M Bueno-de-Mesquita, D S A Nuyten, J Wesseling, et al.
Breast Cancer Research and Treatment|July 1, 2016
The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancerMette S van Ramshorst, Margriet van der Heiden-van der Loo, Gwen M H E Dackus, et al.
Pageof 47

Showing results (131-140 of 467) with videos related to

Sort By:
Pageof 47
FEBS Letters|October 31, 2006
Functional characterization of the promoter for the mouse SPTLC2 gene, which encodes subunit 2 of serine palmitoyltransferaseStephen C Linn, Lindsay M Andras, Hee-Sook Kim, et al.
Breast (Edinburgh, Scotland)|October 3, 2015
St. Gallen endocrine response classes predict recurrence rates over timeR H T Koornstra, K J Beelen, A D Vincent, et al.
JCO Precision Oncology|February 17, 2022
Profound Immunotherapy Response in Mismatch Repair-Deficient Breast CancerMarleen Kok, Hugo M Horlings, Petur Snaebjornsson, et al.
British Journal of Cancer|November 18, 2010
Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signatureM Knauer, F Cardoso, J Wesseling, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Microsimulation Model For The Assessment Of Personalized Cancer Care: The Mapcca Model FrameworkE Van der Meijde, A J van den Eertwegh, R J Fijneman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 10, 2011
Risk of hepatitis B reactivation and the role of novel agents and stem-cell transplantation in multiple myeloma patients with hepatitis B virus (HBV) infectionD H T Mya, S T Han, Y C Linn, et al.
Breast Cancer Research and Treatment|August 19, 2016
Erratum to: The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancerMette S van Ramshorst, Margriet van der Heiden-van der Loo, Gwen M H E Dackus, et al.
Familial Cancer|September 16, 2022
Identifying the BRCA1 c.-107A > T variant in Dutch patients with a tumor BRCA1 promoter hypermethylationVincent M T de Jong, Roelof Pruntel, Tessa G Steenbruggen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 23, 2009
The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatmentJ M Bueno-de-Mesquita, D S A Nuyten, J Wesseling, et al.
Breast Cancer Research and Treatment|July 1, 2016
The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancerMette S van Ramshorst, Margriet van der Heiden-van der Loo, Gwen M H E Dackus, et al.
Pageof 47